Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
Jackson Center, Pennsylvania--(Newsfile Corp. - February 22, 2022) - Halberd Corporation (OTC Pink: HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to an entirely new way of treating PTSD, Traumatic Brain Injury (TBI), Chronic...
2022-02-22 8:00 AM EST
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
Jackson Center, Pennsylvania--(Newsfile Corp. - February 8, 2022) - Halberd Corporation (OTC Pink: HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process. Excess Tau in CSF is associated with the onset and progression of Alzheimer's disease and other neurodegenerative diseases. This is the ninth of ten identified neurodegenerative disease target antigens that Halberd...
2022-02-08 8:00 AM EST
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
Tau has been shown to be important in the development of Alzheimer's Disease.Eradication of tau accomplished without reducing levels of non-target cytokine.Jackson Center, Pennsylvania--(Newsfile Corp. - February 1, 2022) - Halberd Corporation (OTC Pink: HALB) has demonstrated the ability to selectively reduce and control the level of one element in a heterogeneous mixture containing two elements without affecting the levels of the second element. This accomplishment employed Halberd's...
2022-02-01 8:00 AM EST
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
Jackson Center, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Greetings From The CEO And Staff At HALBERD CORPORATION (OTC Pink: HALB)!First of all, I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year!2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is a huge worldwide demand for cures to long standing diseases;There is no effective cure available;Big Pharma had either failed to...
2022-01-25 8:00 AM EST
Halberd, Corp. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
Jackson Center, Pennsylvania--(Newsfile Corp. - January 13, 2022) - Halberd, Corp. (OTC PINK: HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, today announces that they have been able to successfully eliminate Beta Amyloid and Interleukin-4 (IL-4) from synthetic cerebral spinal fluid (CSF) in its latest in-vitro laboratory testing. The Company's latest testing accomplishments support its long-standing...
2022-01-13 8:00 AM EST
Halberd Corporation Now an Official US Government Contractor
Jackson Center, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Halberd Corporation (OTC Pink: HALB) is now registered with the Federal Government's System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in Biotechnology, and Food (Health) Supplement Stores. This opens the door to Halberd to provide products and services to members of the military and various government agencies who...
2022-01-05 8:00 AM EST
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
Jackson Center, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Halberd Corporation (OTC Pink: HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below. Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer's Disease is not very well established,...
2021-12-20 8:00 AM EST
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
Jackson Center, Pennsylvania--(Newsfile Corp. - December 15, 2021) - Halberd Corporation (OTC Pink: HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer's Disease or mild cognitive impairment. Halberd's demonstrated ability to control the levels of IL-12, along with other inflammatory...
2021-12-15 8:00 AM EST
Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
Jackson Center, Pennsylvania--(Newsfile Corp. - December 13, 2021) - Halberd Corporation (OTC Pink: HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer's Disease. Halberd's demonstrated ability to control the levels of IL-1, coupled with its previous successful elimination of TNF-alpha and other...
2021-12-13 8:00 AM EST
Halberd Follow-Up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
Jackson Center, Pennsylvania--(Newsfile Corp. - December 6, 2021) - Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through Halberd's patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation. TNF-alpha is an inflammatory cytokine which has been identified as a...
2021-12-06 8:00 AM EST
Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer's Disease
Jackson Center, Pennsylvania--(Newsfile Corp. - November 22, 2021) - Halberd Corporation (OTC Pink: HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated through exposure to tuned laser irradiation. TNF-α is an inflammatory cytokine which has been identified as a major...
2021-11-22 8:00 AM EST
Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
Jackson Center, Pennsylvania--(Newsfile Corp. - November 8, 2021) - Halberd Corporation (OTC Pink: HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd's intellectual property rights. Halberd works to...
2021-11-08 8:00 AM EST
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer's Disease
Jackson Center, Pennsylvania--(Newsfile Corp. - November 1, 2021) - Halberd Corporation (OTC Pink: HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, IL-6 was virtually eliminated in as little as three minutes of laser radiation exposure. Elevated levels of IL-6 in CSF have been linked to various neurological disorders.Dr....
2021-11-01 8:00 AM EDT
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Jackson Center, Pennsylvania--(Newsfile Corp. - October 25, 2021) - Halberd Corporation (OTC Pink: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate the negative health issues associated with obesity.Halberd's researchers have...
2021-10-25 8:00 AM EDT
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
Jackson Center, Pennsylvania--(Newsfile Corp. - October 20, 2021) - Halberd Corporation's (OTC Pink: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in the blood of those suffering from obesity.Halberd's...
2021-10-20 8:00 AM EDT
Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement
Jackson Center, Pennsylvania--(Newsfile Corp. - October 12, 2021) - Halberd Corporation (OTC Pink: HALB) and GTX Corp (OTC Pink: GTXO) have agreed to work together on various neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, PTSD/CTE (Chronic Traumatic Encephalopathy)/ Traumatic Brain Injury), among others. These diseases are prevalent among seniors, active duty and veteran soldiers, participants in contact sports and millions of people in the general population....
2021-10-12 1:59 PM EDT
Halberd Corporation CEO Letter
Jackson Center, Pennsylvania--(Newsfile Corp. - October 7, 2021) - Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.As reported in the last quarterly update, our research led us to investigate RF...
2021-10-07 8:00 AM EDT
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
Jackson Center, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Halberd Corporation (OTC Pink: HALB) announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd's website at www.vitashieldmax.com.William A. Hartman, Halberd's Chairman, President & CEO, stated, "We are pleased that our product will now also be available through Amazon, and will be able to reach virtually anyone in need of immunity...
2021-10-05 8:00 AM EDT
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
Jackson Center, Pennsylvania--(Newsfile Corp. - September 22, 2021) - Halberd Corp. (OTC Pink: HALB) and heliosDx, a wholly owned company of Rush Net, Inc., an Alpharetta, GA company, announce a Scientific Collaboration Agreement to explore synergies and opportunities mutually beneficial to both companies. A major objective of the agreement is to develop accurate and reliable diagnostic methods by sharing innovative ideas and technologies that will provide the foundation for more effective...
2021-09-22 8:00 AM EDT
Halberd's Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
Jackson Center, Pennsylvania--(Newsfile Corp. - August 16, 2021) - Halberd Corporation's (OTC Pink: HALB) research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station's 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd's on-going research and testing of its groundbreaking, patent protected technology at YSU, which could revolutionize disease treatment worldwide as, reported by Dave Sess. Watch...
2021-08-16 8:00 AM EDT